12:00 AM
 | 
Feb 15, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DPX-0907: Phase I start

This quarter, ImmunoVaccine plans to begin an open-label, U.S Phase I trial to evaluate 0.25 and 1 mL doses of subcutaneous DPX-0907 in about 24 patients with...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >